Skip to main content
Clinical Trials/JPRN-UMIN000015404
JPRN-UMIN000015404
Completed
未知

The prospective study of the clinical efficacy/adverse event of regorafenib in unresectable metastatic and advanced colorectal cancer - Prediction of the Efficacy/Adverse event of Regorafenib in advanced Colorectal cancer (PEARC study)

Department of Clinical Oncology, Akita University Hospital0 sites50 target enrollmentOctober 10, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Colorectal cancer
Sponsor
Department of Clinical Oncology, Akita University Hospital
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 10, 2014
End Date
March 1, 2017
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Department of Clinical Oncology, Akita University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. with potent drug affected activity of CYP3A4 or UGT1A9, and with potent drug affected blood concentration of regorafenib. 2\. Pregnant female, possibly pregnant females and females feeding babies. 3\. with uncontrollable hypertension (systolic \>150 mmHg or diastolic \>90 mmHg even with hypotensives) 4\. with a history of embolism, ischemic heart disease, unstable angina, heart failure or cerebrovascular disease. 5\. with severe allergy. 6\. Any other patients whom the physician in charge of the study judges to be unsuitable.

Outcomes

Primary Outcomes

Not specified

Similar Trials